Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Praxis Precision Medicines (PRAX) Free Cash Flow (2022 - 2025)

Praxis Precision Medicines (PRAX) has 4 years of Free Cash Flow data on record, last reported at -$76.3 million in Q4 2025.

  • For Q4 2025, Free Cash Flow fell 36.0% year-over-year to -$76.3 million; the TTM value through Dec 2025 reached -$249.1 million, down 89.08%, while the annual FY2025 figure was -$249.1 million, 89.08% down from the prior year.
  • Free Cash Flow reached -$76.3 million in Q4 2025 per PRAX's latest filing, down from -$65.1 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$20.9 million in Q1 2024 and bottomed at -$76.3 million in Q4 2025.
  • Average Free Cash Flow over 4 years is -$42.3 million, with a median of -$38.7 million recorded in 2022.
  • Peak YoY movement for Free Cash Flow: surged 47.74% in 2023, then plummeted 154.47% in 2025.
  • A 4-year view of Free Cash Flow shows it stood at -$29.2 million in 2022, then increased by 18.42% to -$23.9 million in 2023, then crashed by 135.2% to -$56.1 million in 2024, then crashed by 36.0% to -$76.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$76.3 million in Q4 2025, -$65.1 million in Q3 2025, and -$54.7 million in Q2 2025.